ClinConnect ClinConnect Logo
Search / Trial NCT04496284

Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen

Launched by REPRODUCTIVE MEDICINE ASSOCIATES OF NEW JERSEY · Jul 31, 2020

Trial Information

Current as of May 18, 2025

Completed

Keywords

ClinConnect Summary

The purpose of this study is to determine if slush nitrogen for embryo vitrification results in higher sustained implantation rates compared to the conventional use of liquid nitrogen. Routine ovarian stimulation, oocyte retrieval and embryology care will ensue. All blastocyst stage embryos will be randomized to either the control (liquid nitrogen) or intervention group (slush nitrogen) and vitrified after trophectoderm biopsy has been performed for PGT-A (preimplantation genetic testing for aneuploidy). A single, chromosomally normal embryo will be transferred in a subsequent frozen embryo...

Gender

FEMALE

Eligibility criteria

  • Major Inclusion Criteria for participants:
  • 1. Patients undergoing IVF stimulation cycle with plan for subsequent frozen embryo transfer (FET)
  • 2. Patients electing preimplantation genetic testing for aneuploidy (PGT-A)
  • 3. Couples electing single embryo transfer (SET)
  • Major Exclusion Criteria for participants:
  • 1. All patients who do not voluntarily give their written consent for participation
  • 2. Under 18 years old, above 42 years old
  • 3. BMI \> 35
  • 4. Maximum day 3 Follicle stimulating hormone (FSH) level of 12 or higher
  • 5. Anti-mullerian hormone (AMH) level less than 1.0 g/mL, tested within previous year
  • 6. Total basal antral follicle count less than 6 follicles
  • 7. Failed more than one previous FET cycle
  • 8. Use of oocyte donation
  • 9. Use of gestational carrier
  • 10. Presence of hydrosalpinges that communicate with endometrial cavity
  • 11. Diagnosis of endometrial insufficiency: prior cycle with maximal endometrial thickness ≤ 6mm, abnormal endometrial pattern (failure to attain a trilaminar appearance), persistent endometrial fluid
  • 12. Uncorrected uterine factor infertility (uterine anomaly, submucosal myomas, uterine septum)
  • 13. Single gene disorder chromosomal rearrangement requiring a more detailed embryonic genetic analysis
  • 14. Male partner with \<100,000 total motile spermatozoa per ejaculate (donor sperm is acceptable)
  • 15. Use of surgical procedures to obtain sperm
  • 16. Couples undergoing IVF for fertility preservation with no immediate plan for subsequent FET (embryo banking)
  • 17. Sex selection
  • 18. Personal history of repeated pregnancy loss (two or more unexplained clinical losses defined by presence of fetal heartbeat)

About Reproductive Medicine Associates Of New Jersey

Reproductive Medicine Associates of New Jersey (RMANJ) is a leading fertility clinic dedicated to advancing reproductive health through innovative clinical practices and cutting-edge research. With a team of highly skilled specialists, RMANJ offers comprehensive services in assisted reproductive technology, including in vitro fertilization (IVF), egg freezing, and fertility preservation. The organization is committed to providing personalized care and leveraging the latest scientific advancements to optimize patient outcomes. Through its robust clinical trial initiatives, RMANJ aims to contribute to the ongoing evolution of reproductive medicine, fostering new therapies and improving access to effective fertility treatments for individuals and couples facing reproductive challenges.

Locations

Basking Ridge, New Jersey, United States

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials